Contract Research Organization Emmes Comes Through on Critical Phase 1 COVID-19 Vaccine Trial

Contract Research Organization Emmes Comes Through on Critical Phase 1 COVID-19 Vaccine Trial

Since 1977, contract research organization (CRO) Emmes has consistently participated in important studies contributing to important drug development initiatives in the United States and beyond. Most recently, the mid-sized CRO, with about 600 professionals, touted its recent participation in the data and statistical analysis support for the critically important Phase 1 clinical trial of the investigational COVID-19 vaccine mRNA-1273. One of the mRNA-based vaccine candidates, Emmes’ employees helped co-author the Preliminary Report about the clinical trial “An mRNA Vaccine against SARS-CoV-2.” Emmes came through on this study and other sponsors should know about this vendor, committed to high impact and high-quality delivery.

Ultimately published in the New England Journal of Medicine on July 14, 2020, three Emmes employees participated as co-authors supporting this important vaccine study. These authors included Jim Albert, who served as leading project manager; Dr. Mat Makowski, senior biostatistician; and Kaitlyn Cross, senior biostatistician. The mid-market CRO set up the electronic data capture system in about a month, reported Jim Albert, noting, “Our t...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee